✦ LIBER ✦

Individual risk prediction model for incident cardiovascular disease: A Bayesian clinical reasoning approach

✍ Scribed by Liu, Yi-Ming; Chen, Sam Li-Sheng; Yen, Amy Ming-Fang; Chen, Hsiu-Hsi

Book ID: 123210964
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 288 KB
Volume: 167
Category: Article
ISSN: 0167-5273
DOI: 10.1016/j.ijcard.2012.05.016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Prediction Model for the Risk of Incid

A Prediction Model for the Risk of Incident Chronic Kidney Disease

✍ Kuo-Liong Chien; Hung-Ju Lin; Bai-Chin Lee; Hsiu-Ching Hsu; Yuan-Teh Lee; Ming-F 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 801 KB

Independent risk for cardiovascular dise

Independent risk for cardiovascular disease predicted by modified continuous score electrocardiographic criteria for 6-year incidence and regression of left ventricular hypertrophy among clinically disease free men: 16-year follow-up for the multiple risk factor intervention trial

✍ Ronald J. Prineas; Pentti M. Rautaharju; Greg Grandits; Richard Crow 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 224 KB

Can individuals with a significant risk

Can individuals with a significant risk for cardiovascular disease be adequately identified by combination of several risk factors? Modelling study based on the Norwegian HUNT 2 population

✍ Halfdan Petursson; Linn Getz; Johann A. Sigurdsson; Irene Hetlevik 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB

Erratum for Anderson JL, et al. “Usefuln

Erratum for Anderson JL, et al. “Usefulness of a Complete Blood Count-Derived Risk Score to Predict Incident Mortality in Patients With Suspected Cardiovascular Disease” Am J Cardiol 2007;99:169–174

📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 40 KB

Utility of a physiologically–based pharm

Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice

✍ Joseph A. Grillo; Ping Zhao; Julie Bullock; Brian P. Booth; Min Lu; Kathy Robie- 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 535 KB

Background: Rivaroxaban is an oral Factor Xa inhibitor. The primary objective of this communication was to quantitatively predict changes in rivaroxaban exposure when individuals with varying degrees of renal impairment are co-administered with another drug that is both a P-gp and a moderate CYP3A4